Sex-specific heart failure burden across the United States: Global burden of disease 1990-2019

Pedro Rvo Salerno1, Zhuo Chen1, Sojin Wass1

  • 1Harrington Heart and Vascular Institute, University Hospitals and Case Western Reserve University School of Medicine, Cleveland, OH.

American Heart Journal
|December 18, 2023
PubMed

Insights

Heart failure (HF) affects males more than females, but the number of older women with HF is rapidly increasing. HF burden varies by age, sex, and region in the US, with Western states showing declines.

Area of Science:

  • Cardiology
  • Public Health
  • Epidemiology

Background:

  • Heart failure (HF) presents unique challenges influenced by biological sex.
  • Understanding sex-specific HF trends in the US is vital for developing targeted interventions.
  • This study analyzes the sex-specific burden of HF in the US from 1990 to 2019.

Purpose of the Study:

  • To analyze the age-adjusted prevalence and disability burden of heart failure (HF) in the US.
  • To examine sex-specific trends in HF prevalence and disability from 1990 to 2019.
  • To identify regional variations in HF burden across US states.

Main Methods:

  • Utilized data from the Global Burden of Disease (GBD) study for the period 1990-2019.
  • Analyzed age-adjusted prevalence and years lived with disability (YLDs) rates per 100,000 individuals.
  • Examined HF burden across US states and regions, stratified by sex and age.

Main Results:

  • In 2019, age-adjusted HF prevalence was higher in males (1,291.2/100,000) than females (926.2/100,000).
  • The absolute number of individuals with HF over 70 years old doubled between 1990 and 2019, with a higher count in females.
  • HF prevalence showed cyclic fluctuations, peaking in the mid-1990s and around 2010; Western states exhibited the greatest relative decline in HF burden.

Conclusions:

  • The US faces a substantial HF burden that varies significantly by age, sex, state, and region.
  • A notable increase in HF cases among women over 70 is projected to continue due to population aging.
  • Targeted interventions considering sex-specific and regional differences are crucial for managing HF effectively.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
395